Health Catalyst, Inc. (NASDAQ:HCAT) Shares Bought by American Century Companies Inc.

American Century Companies Inc. raised its holdings in Health Catalyst, Inc. (NASDAQ:HCAT) by 1.8% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 710,481 shares of the company’s stock after acquiring an additional 12,682 shares during the quarter. American Century Companies Inc.’s holdings in Health Catalyst were worth $5,023,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Point72 Asset Management L.P. boosted its stake in Health Catalyst by 69.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock worth $4,208,000 after purchasing an additional 211,805 shares in the last quarter. Impax Asset Management Group plc increased its position in shares of Health Catalyst by 7.7% in the 4th quarter. Impax Asset Management Group plc now owns 2,750,000 shares of the company’s stock valued at $19,442,000 after acquiring an additional 195,525 shares during the period. Geode Capital Management LLC raised its stake in shares of Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock worth $11,749,000 after purchasing an additional 66,896 shares during the last quarter. State Street Corp lifted its holdings in shares of Health Catalyst by 2.5% during the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after purchasing an additional 28,251 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Health Catalyst in the fourth quarter valued at approximately $110,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $4.01 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst, Inc. has a 1-year low of $3.72 and a 1-year high of $9.24. The company has a market cap of $281.55 million, a PE ratio of -2.97 and a beta of 1.43. The stock’s 50 day simple moving average is $4.89 and its 200-day simple moving average is $6.73.

Insider Activity at Health Catalyst

In related news, COO Daniel Lesueur sold 16,902 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total transaction of $76,397.04. Following the transaction, the chief operating officer now directly owns 216,250 shares in the company, valued at approximately $977,450. The trade was a 7.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Linda Llewelyn sold 6,442 shares of the company’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $5.80, for a total transaction of $37,363.60. Following the sale, the insider now directly owns 92,260 shares of the company’s stock, valued at approximately $535,108. This represents a 6.53 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,530 shares of company stock valued at $299,572. 2.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have commented on HCAT shares. Canaccord Genuity Group decreased their price objective on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 21st. Stephens lowered their price target on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Royal Bank of Canada decreased their price objective on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th. Stifel Nicolaus lowered their target price on Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, February 27th. Finally, KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a research report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.27.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.